Revenue
No reported data
Nuvectis Pharma, Inc. (NVCT)
Price—Loading quote
Net income
2021
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Research & development | $18.2M | $12.9M | $15.4M | $13.2M | $9.5M |
| Operating income | −$27.6M | −$19.8M | −$22.9M | −$19.2M | −$12.9M |
| Net income | −$26.4M | −$19.0M | −$22.3M | −$19.1M | −$12.9M |
| Basic EPSper diluted share | -$1.32 | -$1.11 | -$1.43 | -$1.51 | -$3.02 |
| Diluted EPSper diluted share | -$1.32 | -$1.11 | -$1.43 | -$1.51 | -$3.02 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Nov 5, 2025Form 4 | BENTSUR RONChairman & CEO | BuyCommon Stock | 5.0K | $5.72 | $28.6K | 3.53M |
| Nov 5, 2025Form 4 | Sanchez JuanDirector | BuyCommon Stock | 13.0K | $5.79 | $75.3K | 78.2K |
| Nov 5, 2025Form 4 | Kaplan Matthew L.Director | BuyCommon Stock | 11.0K | $5.84 | $64.2K | 124.8K |
| Oct 27, 2025Form 4 | Mosseri Marlio CharlesTenPercentOwner | BuyCommon Stock · indirect | 72.8K | $6.28 | $457.4K | 3.14M |
| Oct 24, 2025Form 4 | Mosseri Marlio CharlesTenPercentOwner | BuyCommon Stock · indirect | 35.0K | $6.15 | $215.5K | 3.06M |